AbbVie’s Juvmo Won FDA Approval Three Days Before ICER Holds a Public Meeting on Its Value
- The FDA has approved AbbVie‘s tavapadon for adults with Parkinson’s disease under the brand name Juvmo, according to the agency’s novel drug approvals listing, BioSpace reported on 28 September 2026. AbbVie had not disclosed a price or launch plans at the time of reporting.
- The approval rests on the Phase 3 TEMPO programme. TEMPO-3 improved total “on” time in April 2024, TEMPO-1 improved motor function against placebo in September 2024, and TEMPO-2 improved motor and daily-living scores. AbbVie filed in September 2025.
- Tavapadon came with AbbVie’s $8.7bn purchase of Cerevel Therapeutics, closed in August 2024, whose lead asset emraclidine then failed in schizophrenia. Chief commercial officer Jeffrey Stewart put Juvmo’s opportunity at $5bn and said it is less likely than other Parkinson’s drugs to cause sudden sleep episodes.
- ICER’s revised evidence report on 16 September judged tavapadon comparable to available treatments and not cost-effective, set a price benchmark of $4,764 to $6,861 a year as an add-on to levodopa, and declined to set one for early Parkinson’s. Its California panel meets on 1 October.
Access read
AbbVie now has to name a price into a benchmark that already exists.
- The anchor was set first. ICER’s range landed 12 days before approval, which reverses the usual order Synopulse noted on 17 September. Any launch price will be read against $4,764 to $6,861 a year, a range built on ICER’s view that the benefits resemble those of older generic drugs.
- The larger market is the one ICER could not value. ICER declined to benchmark early Parkinson’s, citing uncertainty over benefits and harms, and early disease is the bigger population. How the label covers early against advanced disease will decide how much of Stewart’s $5bn is reachable.
- The tolerability pitch meets ICER’s discontinuation finding. AbbVie is selling fewer sleep attacks; ICER flagged relatively high discontinuation due to adverse events. The 1 October meeting will weigh exactly that trade-off, now for a marketed drug rather than a candidate.